|
|
|
Volumn 113, Issue 22, 2006, Pages
|
|
Viewpoint: Sir Richard Sykes, DSc, FRS, FMedSci
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
NONSTEROID ANTIINFLAMMATORY AGENT;
PENICILLIN G;
THROMBIN INHIBITOR;
TRASTUZUMAB;
XIMELAGATRAN;
BREAST CANCER;
CARDIOLOGY;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
DRUG METABOLISM;
DRUG RESEARCH;
DRUG SAFETY;
DRUG WITHDRAWAL;
HUMAN;
LEUKEMIA;
LIVER TOXICITY;
MULTIPLE ORGAN FAILURE;
MULTIPLE SCLEROSIS;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
UNSPECIFIED SIDE EFFECT;
ARTICLE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG TOXICITY;
INCIDENCE;
INTERVIEW;
LEGAL ASPECT;
METHODOLOGY;
RISK ASSESSMENT;
UNITED KINGDOM;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG HYPERSENSITIVITY;
DRUG INDUSTRY;
DRUG TOXICITY;
ENGLAND;
HUMANS;
INCIDENCE;
RISK ASSESSMENT;
|
|
EID: 33745150419
PISSN: 00097322
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (1)
|
|
References (0)
|
